NasdaqCM:JYNT

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. More Details


Snowflake Analysis

Outstanding track record with high growth potential.

Share Price & News

How has Joint's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: JYNT has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

1.1%

JYNT

1.6%

US Healthcare

1.0%

US Market


1 Year Return

-6.1%

JYNT

15.9%

US Healthcare

13.6%

US Market

Return vs Industry: JYNT underperformed the US Healthcare industry which returned 16.1% over the past year.

Return vs Market: JYNT underperformed the US Market which returned 14.2% over the past year.


Shareholder returns

JYNTIndustryMarket
7 Day1.1%1.6%1.0%
30 Day-3.2%-4.4%-0.4%
90 Day26.4%1.1%8.9%
1 Year-6.1%-6.1%17.4%15.9%16.2%13.6%
3 Year304.3%304.3%29.1%23.4%40.2%30.8%
5 Year153.2%153.2%52.8%42.1%89.6%68.2%

Price Volatility Vs. Market

How volatile is Joint's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Joint undervalued compared to its fair value and its price relative to the market?

34.2%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: JYNT ($17.3) is trading below our estimate of fair value ($26.98)

Significantly Below Fair Value: JYNT is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: JYNT is poor value based on its PE Ratio (84.7x) compared to the US Healthcare industry average (22.4x).

PE vs Market: JYNT is poor value based on its PE Ratio (84.7x) compared to the US market (18.6x).


Price to Earnings Growth Ratio

PEG Ratio: JYNT is poor value based on its PEG Ratio (1.3x)


Price to Book Ratio

PB vs Industry: JYNT is overvalued based on its PB Ratio (32.3x) compared to the US Healthcare industry average (2.9x).


Next Steps

Future Growth

How is Joint forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

64.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: JYNT's forecast earnings growth (64% per year) is above the savings rate (2.2%).

Earnings vs Market: JYNT's earnings (64% per year) are forecast to grow faster than the US market (23.3% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: JYNT's revenue (23.7% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: JYNT's revenue (23.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if JYNT's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Joint performed over the past 5 years?

56.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: JYNT has high quality earnings.

Growing Profit Margin: JYNT's current net profit margins (5.4%) are higher than last year (4%).


Past Earnings Growth Analysis

Earnings Trend: JYNT has become profitable over the past 5 years, growing earnings by 56.2% per year.

Accelerating Growth: JYNT's earnings growth over the past year (71.6%) exceeds its 5-year average (56.2% per year).

Earnings vs Industry: JYNT earnings growth over the past year (71.6%) exceeded the Healthcare industry 31.1%.


Return on Equity

High ROE: JYNT's Return on Equity (37.8%) is considered high.


Next Steps

Financial Health

How is Joint's financial position?


Financial Position Analysis

Short Term Liabilities: JYNT's short term assets ($18.8M) exceed its short term liabilities ($14.8M).

Long Term Liabilities: JYNT's short term assets ($18.8M) do not cover its long term liabilities ($27.3M).


Debt to Equity History and Analysis

Debt Level: JYNT's debt to equity ratio (63%) is considered high.

Reducing Debt: JYNT's debt to equity ratio has increased from 5.1% to 63% over the past 5 years.

Debt Coverage: JYNT's debt is well covered by operating cash flow (163.3%).

Interest Coverage: Insufficient data to determine if JYNT's interest payments on its debt are well covered by EBIT.


Balance Sheet


Next Steps

Dividend

What is Joint current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate JYNT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate JYNT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if JYNT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if JYNT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of JYNT's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.1yrs

Average management tenure


CEO

Peter Holt (61 yo)

4.08yrs

Tenure

US$912,685

Compensation

Mr. Peter D. Holt has been Chief Executive Officer of The Joint Corp. since August 11, 2016 and has been its President since January 2017. Mr. Holt served as Interim Principal Financial Officer at The Join ...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD912.69K) is about average for companies of similar size in the US market ($USD1.28M).

Compensation vs Earnings: Peter's compensation has increased by more than 20% in the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Peter Holt
CEO, President & Director4.08yrsUS$912.69k1.74%
$ 4.3m
Jake Singleton
Chief Financial Officer1.83yrsUS$303.41k0.49%
$ 1.2m
Jorge Armenteros
Vice President of Operations3.67yrsno datano data
Jason Greenwood
Vice President of Marketingno datano datano data
Amy Karroum
Vice President of Human Resourcesno datano datano data
Craig Colmar
Secretary10.5yrsUS$75.27kno data
Steven Knauf
Director of Chiropractic & Compliance4.92yrsno datano data
Eric Simon
Vice President of Franchise Sales & Developmentno datano datano data
David Glover
Regional Developer for West Lake Hillsno datano datano data
Richard Matthews
Director of Real Estate Researchno datano datano data
Teresa Cueto-DiGiuseppe
Multi-Unit Franchiseeno datano datano data
Manjula Sriram
Vice Preident of Information Technologyno datano datano data

4.1yrs

Average Tenure

61yo

Average Age

Experienced Management: JYNT's management team is considered experienced (4.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Peter Holt
CEO, President & Director4.08yrsUS$912.69k1.74%
$ 4.3m
Glenn Krevlin
Independent Director1.33yrsUS$60.00k2.2%
$ 5.5m
James Amos
Independent Director5yrsUS$85.00k0.62%
$ 1.5m
Suzanne Decker
Independent Director3.25yrsUS$82.50k0.15%
$ 365.6k
Matthew Rubel
Independent Lead Director3.08yrsUS$90.00k0.19%
$ 481.0k
Ronald DaVella
Independent Director5.83yrsUS$92.50k0.037%
$ 91.5k
Abe Hong
Independent Director2.25yrsUS$85.00k0.076%
$ 189.0k

3.3yrs

Average Tenure

61yo

Average Age

Experienced Board: JYNT's board of directors are considered experienced (3.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

The Joint Corp.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: The Joint Corp.
  • Ticker: JYNT
  • Exchange: NasdaqCM
  • Founded: 2010
  • Industry: Health Care Facilities
  • Sector: Healthcare
  • Market Cap: US$248.692m
  • Shares outstanding: 14.01m
  • Website: https://www.thejoint.com

Number of Employees


Location

  • The Joint Corp.
  • 16767 North Perimeter Drive
  • Suite 240
  • Scottsdale
  • Arizona
  • 85260
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
JYNTNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDNov 2014
1JODB (Deutsche Boerse AG)YesCommon StockDEEURNov 2014

Biography

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics in the United States. The company operates through two segments, Corporate Clinics and Franchise Operations. It operates ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/19 06:06
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.